Summit Therapeutics Inc. (SMMT) › Cash & EquivalentsSummit Therapeutics Inc. (SMMT) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2019-12-31: $63.84M2020-12-31: $66.42M2021-12-31: $71.79M2022-12-31: $348.61M2023-12-31: $71.42M2024-12-31: $104.86M2025-12-31: $225.27M$225.27M2019-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$225.27M+114.8%2026-02-23Balance as of period end2024-12-31$104.86M+46.8%2026-02-23Balance as of period end2023-12-31$71.42M-79.5%2026-02-23Balance as of period end2022-12-31$348.61M+385.6%2025-02-24Balance as of period end2021-12-31$71.79M+8.1%2023-03-09Balance as of period end2020-12-31$66.42M+4.0%2021-03-31Balance as of period end2019-12-31$63.84M—2021-03-31Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)